Last reviewed · How we verify

Standard medication for variant angina — Competitive Intelligence Brief

Standard medication for variant angina (Standard medication for variant angina) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Calcium channel blocker. Area: Cardiovascular.

marketed Calcium channel blocker L-type voltage-gated calcium channel Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Standard medication for variant angina (Standard medication for variant angina) — Seoul National University Hospital. Calcium channel blockers relax coronary artery smooth muscle to prevent vasospasm and improve blood flow in variant angina.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Standard medication for variant angina TARGET Standard medication for variant angina Seoul National University Hospital marketed Calcium channel blocker L-type voltage-gated calcium channel
Candesartan cilexetil/Amlodipine besylate Candesartan cilexetil/Amlodipine besylate HK inno.N Corporation marketed Angiotensin II receptor blocker / Calcium channel blocker combination AT1 receptor (angiotensin II type 1 receptor) / L-type voltage-gated calcium channel
Calcium Channel Blockers Calcium Channel Blockers Hospital de Clinicas de Porto Alegre marketed Calcium channel blocker L-type voltage-gated calcium channel
Amlodipine plus Hydrochlorothiazide Amlodipine plus Hydrochlorothiazide University of Abuja marketed Calcium channel blocker + thiazide diuretic combination L-type voltage-gated calcium channel (amlodipine); sodium-chloride cotransporter (hydrochlorothiazide)
Nifedipine GITS Nifedipine GITS Peking University First Hospital marketed Calcium channel blocker (dihydropyridine) L-type voltage-gated calcium channel
Telmisartan + Amlodipine Telmisartan + Amlodipine Daewon Pharmaceutical Co., Ltd. marketed Angiotensin II receptor blocker + Calcium channel blocker combination AT1 receptor (angiotensin II type 1 receptor) and L-type voltage-gated calcium channels
Losartan and Amlodipine Losartan and Amlodipine Centro Universitario de Ciencias de la Salud, Mexico marketed Angiotensin II receptor antagonist + Calcium channel blocker combination AT1 receptor (losartan); L-type voltage-gated calcium channel (amlodipine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Calcium channel blocker class)

  1. Shenzhen Ausa Pharmed Co.,Ltd · 2 drugs in this class
  2. Boryung Pharmaceutical Co., Ltd · 2 drugs in this class
  3. Ain Shams University · 1 drug in this class
  4. Bioprojet · 1 drug in this class
  5. Bristol-Myers Squibb · 1 drug in this class
  6. GlaxoSmithKline · 1 drug in this class
  7. Handok Inc. · 1 drug in this class
  8. Hasten Biopharmaceutical Co., Ltd. · 1 drug in this class
  9. Hospital de Clinicas de Porto Alegre · 1 drug in this class
  10. Laboratorios Richmond S.A.C.I.F. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Standard medication for variant angina — Competitive Intelligence Brief. https://druglandscape.com/ci/standard-medication-for-variant-angina. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: